Interestingly, a recent epidemiological study has showed that, naftopidil, a naphthalene-based α1-adrenoceptor antagonist, reduces prostate cancer incidence due to its blocking effect on TGF-β signaling and Bcl-2 expression 60, which is consistent with our finding that lower levels of TGF-β signaling and Bcl-2 expression correlated with prolonged disease free survival in patients with advanced prostate cancer. The gene discussed is BCL2; the disease is Familial prostate cancer.